Fosun Pharma Unit's Luvometinib Gets China Nod for Langerhans Cell Histiocytosis Drug Indication

MT Newswires Live

06/16

Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) said the drug registration application for an additional indication of Luvometinib Tablets was approved by China's National Medical Products Administration, according to a Monday Hong Kong bourse filing.

Shares of the pharmaceutical company were down nearly 2% in Tuesday afternoon trading.

The approved indication is for the treatment of pediatric patients aged two years and older with relapsed or refractory Langerhans cell histiocytosis.

The drug was developed by Shanghai Fosun Pharmaceutical Industrial Development, a unit of Fosun Pharmaceutical.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2643739464"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2643739464\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2643739464?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-16 14:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2643739464","market":"us","top_or_hot":-1,"title":"Fosun Pharma Unit's Luvometinib Gets China Nod for Langerhans Cell Histiocytosis Drug Indication","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/SFOSF\">Shanghai Fosun</a> Pharmaceutical (SHA:600196, HKG:2196) said the drug registration application for an additional indication of Luvometinib Tablets was approved by China's National Medical Products Administration, according to a Monday Hong Kong bourse filing.</p><p>Shares of the pharmaceutical company were down nearly 2% in Tuesday afternoon trading.</p><p>The approved indication is for the treatment of pediatric patients aged two years and older with relapsed or refractory Langerhans cell histiocytosis.</p><p>The drug was developed by <a href=\"https://laohu8.com/S/600196\">Shanghai Fosun</a> Pharmaceutical Industrial Development, a unit of Fosun Pharmaceutical.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fosun Pharma Unit's Luvometinib Gets China Nod for Langerhans Cell Histiocytosis Drug Indication</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFosun Pharma Unit's Luvometinib Gets China Nod for Langerhans Cell Histiocytosis Drug Indication\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-06-16 14:28</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/SFOSF\">Shanghai Fosun</a> Pharmaceutical (SHA:600196, HKG:2196) said the drug registration application for an additional indication of Luvometinib Tablets was approved by China's National Medical Products Administration, according to a Monday Hong Kong bourse filing.</p><p>Shares of the pharmaceutical company were down nearly 2% in Tuesday afternoon trading.</p><p>The approved indication is for the treatment of pediatric patients aged two years and older with relapsed or refractory Langerhans cell histiocytosis.</p><p>The drug was developed by <a href=\"https://laohu8.com/S/600196\">Shanghai Fosun</a> Pharmaceutical Industrial Development, a unit of Fosun Pharmaceutical.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0183","symbol_name":"MSCI概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2643739464","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2643739464","pubTimestamp":1781591317,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Shanghai Fosun Pharmaceutical  said the drug registration application for an additional indication of Luvometinib Tablets was approved by China's National Medical Products Administration, according to a Monday Hong Kong bourse filing.Shares of the pharmaceutical company were down nearly 2% in Tuesday afternoon trading.The approved indication is for the treatment of pediatric patients aged two years and older with relapsed or refractory Langerhans cell histiocytosis.The drug was developed by Shanghai Fosun Pharmaceutical Industrial Development, a unit of Fosun Pharmaceutical.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600196":"复星医药","BK0183":"MSCI概念","BK0188":"融资融券","BK1515":"抗疫概念","BK1191":"制药","BK0096":"民营医院","BK0012":"证金概念","BK1593":"医美概念股","BK0196":"行业龙头","BK0175":"白马股","BK0187":"一线龙头","BK0060":"抗癌","02196":"复星医药","BK0028":"国家队","BK0239":"医药制造"},"translate_title":"复星医药子公司Luvometinib朗格汉斯细胞组织细胞增生症药物适应症获得中国认可","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":0.9,"02196":0.9},"content_text":"Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) said the drug registration application for an additional indication of Luvometinib Tablets was approved by China's National Medical Products Administration, according to a Monday Hong Kong bourse filing.Shares of the pharmaceutical company were down nearly 2% in Tuesday afternoon trading.The approved indication is for the treatment of pediatric patients aged two years and older with relapsed or refractory Langerhans cell histiocytosis.The drug was developed by Shanghai Fosun Pharmaceutical Industrial Development, a unit of Fosun Pharmaceutical.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}